Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
Identifieur interne : 000510 ( Main/Exploration ); précédent : 000509; suivant : 000511Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
Auteurs : Luciano Macchione [Italie] ; Giuseppe Mucciardi ; Alessandro Gali' ; Antonina Di Benedetto ; Salvatore Butticè ; Carlo MagnoSource :
- International urology and nephrology [ 1573-2584 ] ; 2013.
Descripteurs français
- KwdFr :
- Administration par voie orale, Adulte d'âge moyen, Antiagrégants plaquettaires (usage thérapeutique), Anticoagulants (administration et posologie), Cathétérisme urinaire, Durée du séjour, Durée opératoire, Humains, Hyperplasie de la prostate (), Hyperplasie de la prostate (sang), Hématurie (étiologie), Indice de gravité médicale, Lasers à solide (effets indésirables), Lasers à solide (usage thérapeutique), Mâle, Prostatisme (), Prostatisme (étiologie), Qualité de vie, Sodium (sang), Sujet âgé, Études rétrospectives.
- MESH :
- administration et posologie : Anticoagulants.
- effets indésirables : Lasers à solide.
- sang : Hyperplasie de la prostate, Sodium.
- usage thérapeutique : Antiagrégants plaquettaires, Lasers à solide.
- étiologie : Hématurie, Prostatisme.
- Administration par voie orale, Adulte d'âge moyen, Cathétérisme urinaire, Durée du séjour, Durée opératoire, Humains, Hyperplasie de la prostate, Indice de gravité médicale, Mâle, Prostatisme, Qualité de vie, Sujet âgé, Études rétrospectives.
English descriptors
- KwdEn :
- Administration, Oral, Aged, Anticoagulants (administration & dosage), Hematuria (etiology), Humans, Lasers, Solid-State (adverse effects), Lasers, Solid-State (therapeutic use), Length of Stay, Male, Middle Aged, Operative Time, Platelet Aggregation Inhibitors (therapeutic use), Prostatic Hyperplasia (blood), Prostatic Hyperplasia (complications), Prostatic Hyperplasia (surgery), Prostatism (etiology), Prostatism (surgery), Quality of Life, Retrospective Studies, Severity of Illness Index, Sodium (blood), Urinary Catheterization.
- MESH :
- chemical , administration & dosage : Anticoagulants.
- adverse effects : Lasers, Solid-State.
- blood : Prostatic Hyperplasia, Sodium.
- complications : Prostatic Hyperplasia.
- etiology : Hematuria, Prostatism.
- surgery : Prostatic Hyperplasia, Prostatism.
- therapeutic use : Lasers, Solid-State, Platelet Aggregation Inhibitors.
- Administration, Oral, Aged, Humans, Length of Stay, Male, Middle Aged, Operative Time, Quality of Life, Retrospective Studies, Severity of Illness Index, Urinary Catheterization.
Abstract
The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.
DOI: 10.1007/s11255-013-0487-y
PubMed: 23892531
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000260
- to stream PubMed, to step Curation: 000260
- to stream PubMed, to step Checkpoint: 000260
- to stream Ncbi, to step Merge: 000715
- to stream Ncbi, to step Curation: 000715
- to stream Ncbi, to step Checkpoint: 000715
- to stream Main, to step Merge: 000510
- to stream Main, to step Curation: 000510
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.</title><author><name sortKey="Macchione, Luciano" sort="Macchione, Luciano" uniqKey="Macchione L" first="Luciano" last="Macchione">Luciano Macchione</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina</wicri:regionArea><wicri:noRegion>Messina</wicri:noRegion></affiliation></author><author><name sortKey="Mucciardi, Giuseppe" sort="Mucciardi, Giuseppe" uniqKey="Mucciardi G" first="Giuseppe" last="Mucciardi">Giuseppe Mucciardi</name></author><author><name sortKey="Gali, Alessandro" sort="Gali, Alessandro" uniqKey="Gali A" first="Alessandro" last="Gali'">Alessandro Gali'</name></author><author><name sortKey="Di Benedetto, Antonina" sort="Di Benedetto, Antonina" uniqKey="Di Benedetto A" first="Antonina" last="Di Benedetto">Antonina Di Benedetto</name></author><author><name sortKey="Buttice, Salvatore" sort="Buttice, Salvatore" uniqKey="Buttice S" first="Salvatore" last="Butticè">Salvatore Butticè</name></author><author><name sortKey="Magno, Carlo" sort="Magno, Carlo" uniqKey="Magno C" first="Carlo" last="Magno">Carlo Magno</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="doi">10.1007/s11255-013-0487-y</idno><idno type="RBID">pubmed:23892531</idno><idno type="pmid">23892531</idno><idno type="wicri:Area/PubMed/Corpus">000260</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000260</idno><idno type="wicri:Area/PubMed/Curation">000260</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000260</idno><idno type="wicri:Area/PubMed/Checkpoint">000260</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000260</idno><idno type="wicri:Area/Ncbi/Merge">000715</idno><idno type="wicri:Area/Ncbi/Curation">000715</idno><idno type="wicri:Area/Ncbi/Checkpoint">000715</idno><idno type="wicri:Area/Main/Merge">000510</idno><idno type="wicri:Area/Main/Curation">000510</idno><idno type="wicri:Area/Main/Exploration">000510</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.</title><author><name sortKey="Macchione, Luciano" sort="Macchione, Luciano" uniqKey="Macchione L" first="Luciano" last="Macchione">Luciano Macchione</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina</wicri:regionArea><wicri:noRegion>Messina</wicri:noRegion></affiliation></author><author><name sortKey="Mucciardi, Giuseppe" sort="Mucciardi, Giuseppe" uniqKey="Mucciardi G" first="Giuseppe" last="Mucciardi">Giuseppe Mucciardi</name></author><author><name sortKey="Gali, Alessandro" sort="Gali, Alessandro" uniqKey="Gali A" first="Alessandro" last="Gali'">Alessandro Gali'</name></author><author><name sortKey="Di Benedetto, Antonina" sort="Di Benedetto, Antonina" uniqKey="Di Benedetto A" first="Antonina" last="Di Benedetto">Antonina Di Benedetto</name></author><author><name sortKey="Buttice, Salvatore" sort="Buttice, Salvatore" uniqKey="Buttice S" first="Salvatore" last="Butticè">Salvatore Butticè</name></author><author><name sortKey="Magno, Carlo" sort="Magno, Carlo" uniqKey="Magno C" first="Carlo" last="Magno">Carlo Magno</name></author></analytic><series><title level="j">International urology and nephrology</title><idno type="eISSN">1573-2584</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Anticoagulants (administration & dosage)</term><term>Hematuria (etiology)</term><term>Humans</term><term>Lasers, Solid-State (adverse effects)</term><term>Lasers, Solid-State (therapeutic use)</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Operative Time</term><term>Platelet Aggregation Inhibitors (therapeutic use)</term><term>Prostatic Hyperplasia (blood)</term><term>Prostatic Hyperplasia (complications)</term><term>Prostatic Hyperplasia (surgery)</term><term>Prostatism (etiology)</term><term>Prostatism (surgery)</term><term>Quality of Life</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Sodium (blood)</term><term>Urinary Catheterization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term><term>Adulte d'âge moyen</term><term>Antiagrégants plaquettaires (usage thérapeutique)</term><term>Anticoagulants (administration et posologie)</term><term>Cathétérisme urinaire</term><term>Durée du séjour</term><term>Durée opératoire</term><term>Humains</term><term>Hyperplasie de la prostate ()</term><term>Hyperplasie de la prostate (sang)</term><term>Hématurie (étiologie)</term><term>Indice de gravité médicale</term><term>Lasers à solide (effets indésirables)</term><term>Lasers à solide (usage thérapeutique)</term><term>Mâle</term><term>Prostatisme ()</term><term>Prostatisme (étiologie)</term><term>Qualité de vie</term><term>Sodium (sang)</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticoagulants</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lasers, Solid-State</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Prostatic Hyperplasia</term><term>Sodium</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lasers à solide</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hematuria</term><term>Prostatism</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hyperplasie de la prostate</term><term>Sodium</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term><term>Prostatism</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term><term>Platelet Aggregation Inhibitors</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiagrégants plaquettaires</term><term>Lasers à solide</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hématurie</term><term>Prostatisme</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Humans</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Operative Time</term><term>Quality of Life</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Urinary Catheterization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Adulte d'âge moyen</term><term>Cathétérisme urinaire</term><term>Durée du séjour</term><term>Durée opératoire</term><term>Humains</term><term>Hyperplasie de la prostate</term><term>Indice de gravité médicale</term><term>Mâle</term><term>Prostatisme</term><term>Qualité de vie</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Buttice, Salvatore" sort="Buttice, Salvatore" uniqKey="Buttice S" first="Salvatore" last="Butticè">Salvatore Butticè</name><name sortKey="Di Benedetto, Antonina" sort="Di Benedetto, Antonina" uniqKey="Di Benedetto A" first="Antonina" last="Di Benedetto">Antonina Di Benedetto</name><name sortKey="Gali, Alessandro" sort="Gali, Alessandro" uniqKey="Gali A" first="Alessandro" last="Gali'">Alessandro Gali'</name><name sortKey="Magno, Carlo" sort="Magno, Carlo" uniqKey="Magno C" first="Carlo" last="Magno">Carlo Magno</name><name sortKey="Mucciardi, Giuseppe" sort="Mucciardi, Giuseppe" uniqKey="Mucciardi G" first="Giuseppe" last="Mucciardi">Giuseppe Mucciardi</name></noCountry><country name="Italie"><noRegion><name sortKey="Macchione, Luciano" sort="Macchione, Luciano" uniqKey="Macchione L" first="Luciano" last="Macchione">Luciano Macchione</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000510 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000510 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23892531
|texte= Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23892531" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |